Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Laura Lazo"'
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Autor:
Ernesto Marcos, Alienys Izquierdo, Lázaro Gil, María G. Guzmán, Laura Lazo, Lisset Hermida, Gerardo Guillén, Aracelys Blanco, Edith Suzarte, Laura Hernandez, Iris Valdés, Yusleidi Pérez, Karem Cobas, Yaremis Romero, Pedro Puentes
Publikováno v:
The Journal of Immunology. 197:3597-3606
Despite the considerable effort that has been invested in elucidating the mechanisms of protection and immunopathogenesis associated with dengue virus infections, a reliable correlate of protection against the disease remains to be found. Neutralizin
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology
Frontiers in Immunology
Dengue is one of the most important diseases transmitted by mosquitoes. Dengvaxia®, a vaccine registered in several countries, cannot be administered to non-immune individuals and children younger than 9 years old, due to safety reasons. There are t
Autor:
Thomas Kariuki, Prisilla Kimiti, Lucy Ochola, Gerardo Guillén, Iris Valdés, María G. Guzmán, Lázaro Gil, Ernesto Marcos, James Ndung'u, Lisset Hermida, Peris Ambala, Mayling Alvarez, Alienys Izquierdo, Laura Lazo, Rikoi Hitler, Edith Suzarte
Publikováno v:
Immunology & Cell Biology. 93:57-66
Previously, we reported the ability of the chimeric protein DIIIC-2 (domain III of the dengue envelope protein fused to the capsid protein of dengue-2 virus), to induce immunity and protection in mice, when it is highly aggregated with a non-defined
Autor:
Lázaro Gil, Phuong Yen, Ngyen D Hien, María G. Guzmán, Gerardo Guillén, Laura Lazo, Mayling Alvarez, Karem Cobas, Rosa Ramirez, Edith Suzarte, Lisset Hermida, Yusleidi Pérez, Le T Dung, Iris Valdés, Ernesto Marcos
Publikováno v:
Clinical & Translational Immunology
Tetra DIIIC is a vaccine candidate against dengue virus (DENV) composed by four chimeric proteins that fuse the domain III of the envelope protein of each virus to the corresponding capsid protein. Containing B- and T-cell epitopes, these proteins fo
Autor:
Gerardo Enrique Guillen Nieto, Lázaro Gil González, Iris Valdes Prado, Jorge Castro Velazco, Lisset Hermida Cruz, Karem Cobas Acosta, Nguyen Dang Hien, Edith Suzarte Portal, Le Trung Dung, Laura Lazo Vazquez, Phuong Yen, Ernesto Marcos López
Publikováno v:
Clinical & Translational Immunology
One of the major problems faced for the development of a vaccine against Dengue virus is the lack of a suitable animal model. Although non-human primates do not show overt signs of disease, these animals develop viremia after the infection and are th
Autor:
Edith Suzarte, María G. Guzmán, Ernesto Marcos, Yusleydis Pérez, Lázaro Gil, Gerardo Guillén, Alienys Izquierdo, Laura Lazo, Aracelys Blanco, Yaremis Romero, José Suárez Alba, Iris Valdés, Lisset Hermida, Julio Ancizar, Karen Cobas
Publikováno v:
Immunology letters. 176
Despite the many efforts made by the scientific community in the development of vaccine candidates against dengue virus (DENV), no vaccine has been licensed up to date. Although the immunopathogenesis associated to the disease is a key factor to take
Autor:
Iris Valdés, Carlos López, Laura Lazo, Ailyn Gambe, Ruby Alonso, Yaremis Romero, Gerardo Guillén, Ernesto Marcos, Lisset Hermida, María G. Guzmán, Lázaro Gil, Jorge Martín
Publikováno v:
International Immunology. 21:1175-1183
Virus-like particles are a highly effective type of subunit vaccine that mimics the overall structure of virus particles without containing infectious genetic material. In this work, a particulate form of the recombinant capsid protein from dengue-2
Autor:
Gerardo Guillén, Lázaro López, Laura Lazo, Yusleydis Pérez, Alienys Izquierdo, Ernesto Marcos, Jorge Fernandez de Castro, María G. Guzmán, Maylin Álvarez, Lázaro Gil, Iris Valdés, Lisset Hermida, Edith Suzarte, Angélica García, Yaremis Romero
Publikováno v:
International immunology. 27(8)
Our group developed a subunit vaccine candidate against dengue virus based on two different viral regions: the domain III of the envelope protein and the capsid protein. The novel chimeric protein from dengue-2 virus [domain III-capsid (DIIIC-2)], wh
Autor:
Ernesto Marcos, María G. Guzmán, Lázaro Gil, Laura Lazo, Gerardo Guillén, Yaremis Romero, Iris Valdés, Lisset Hermida, Jorge Fernandez de Castro, Pedro Puente
Publikováno v:
Clinical and vaccine immunology : CVI. 18(3)
Use of a heterologous prime-boost strategy based on a combination of nonreplicative immunogens and candidate attenuated virus vaccines against dengue virus in the same schedule is an attractive approach. These combinations may result in a condensed i